MX375724B - Compuestos y métodos para la inhibición de jak. - Google Patents

Compuestos y métodos para la inhibición de jak.

Info

Publication number
MX375724B
MX375724B MX2018003590A MX2018003590A MX375724B MX 375724 B MX375724 B MX 375724B MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 375724 B MX375724 B MX 375724B
Authority
MX
Mexico
Prior art keywords
sup
sub
methyl
compounds
ethyl
Prior art date
Application number
MX2018003590A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003590A (es
Inventor
Birgitta Margareta Åstrand Annika
Cluadio Edmundo Chuaqui
Dedong Wu
James Mccabe
Jason Grant Kettle
Jon James Winter-Holt
Linette Lys Ruston
Magnus K Nilsson
Melissa Marie Vasbinder
Neil Patrick Grimster
Qibin Su
Richard Donald Woessner
Sameer Kawatkar
Tudor Grecu
Wenzhan Yang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2018003590A publication Critical patent/MX2018003590A/es
Publication of MX375724B publication Critical patent/MX375724B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2018003590A 2015-09-25 2016-09-22 Compuestos y métodos para la inhibición de jak. MX375724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Publications (2)

Publication Number Publication Date
MX2018003590A MX2018003590A (es) 2018-11-29
MX375724B true MX375724B (es) 2025-03-06

Family

ID=56979589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003590A MX375724B (es) 2015-09-25 2016-09-22 Compuestos y métodos para la inhibición de jak.

Country Status (17)

Country Link
US (5) US9714236B2 (enExample)
EP (2) EP4219482A1 (enExample)
JP (1) JP6767491B2 (enExample)
KR (2) KR20250035597A (enExample)
CN (4) CN111606893B (enExample)
AR (1) AR106138A1 (enExample)
AU (1) AU2016328764B2 (enExample)
BR (1) BR112018005833B1 (enExample)
CA (1) CA2995430C (enExample)
DK (1) DK3353168T3 (enExample)
ES (1) ES2956642T3 (enExample)
MX (1) MX375724B (enExample)
PT (1) PT3353168T (enExample)
RU (1) RU2760359C2 (enExample)
TW (1) TWI740843B (enExample)
WO (1) WO2017050938A1 (enExample)
ZA (1) ZA201800782B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035597A (ko) * 2015-09-25 2025-03-12 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
MX390625B (es) * 2017-01-17 2025-03-19 Astrazeneca Ab Inhibidores selectivos de jak1.
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CN118580223A (zh) * 2018-07-18 2024-09-03 阿斯利康(瑞典)有限公司 抑制jak的化合物的昔萘酸盐
CN112823159B (zh) * 2018-09-21 2024-03-01 上海轶诺药业有限公司 一类具有激酶抑制活性的芳香杂环类化合物
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021012749A (es) * 2019-04-19 2021-11-18 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidor selectivo de la jak1 cinasa.
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
CN114269736B (zh) * 2020-11-26 2024-02-02 科辉智药(深圳)新药研究中心有限公司 一种酰胺化合物、药物组合物及其应用
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560454C (en) * 2004-03-30 2013-05-21 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007089768A2 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130225615A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体
SG190839A1 (en) * 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012116247A1 (en) * 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012177606A1 (en) * 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
KR20250035597A (ko) * 2015-09-25 2025-03-12 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법

Also Published As

Publication number Publication date
HK1259422A1 (zh) 2019-11-29
RU2760359C2 (ru) 2021-11-24
ZA201800782B (en) 2018-12-19
AR106138A1 (es) 2017-12-13
AU2016328764A1 (en) 2018-02-22
EP3353168B1 (en) 2023-08-30
TW201730186A (zh) 2017-09-01
DK3353168T3 (da) 2023-10-02
PT3353168T (pt) 2023-09-20
US20220119372A1 (en) 2022-04-21
KR20180058719A (ko) 2018-06-01
CN111646980A (zh) 2020-09-11
US20190092760A1 (en) 2019-03-28
US10167276B2 (en) 2019-01-01
US20170320857A1 (en) 2017-11-09
US9714236B2 (en) 2017-07-25
MX2018003590A (es) 2018-11-29
CN111646980B (zh) 2021-08-27
RU2018112993A3 (enExample) 2020-01-30
EP4219482A1 (en) 2023-08-02
JP2018529770A (ja) 2018-10-11
CN111606893B (zh) 2021-05-04
CN108368091B (zh) 2020-08-11
WO2017050938A1 (en) 2017-03-30
CN111848586A (zh) 2020-10-30
AU2016328764B2 (en) 2020-07-09
BR112018005833B1 (pt) 2023-10-10
KR102774784B1 (ko) 2025-02-27
US20170088543A1 (en) 2017-03-30
TWI740843B (zh) 2021-10-01
CN111848586B (zh) 2024-05-03
CA2995430A1 (en) 2017-03-30
US12319670B2 (en) 2025-06-03
US20210078981A1 (en) 2021-03-18
JP6767491B2 (ja) 2020-10-14
US11247983B2 (en) 2022-02-15
ES2956642T3 (es) 2023-12-26
CA2995430C (en) 2023-07-11
RU2018112993A (ru) 2019-10-28
BR112018005833A2 (pt) 2018-10-16
CN111606893A (zh) 2020-09-01
EP3353168A1 (en) 2018-08-01
CN108368091A (zh) 2018-08-03
US10654835B2 (en) 2020-05-19
KR20250035597A (ko) 2025-03-12

Similar Documents

Publication Publication Date Title
MX375724B (es) Compuestos y métodos para la inhibición de jak.
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
EA201691302A1 (ru) Новые гетероциклические соединения
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
AU2018253590A1 (en) Imidazopyridazine compounds
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration